U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H11N3O.ClH
Molecular Weight 201.653
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Betovumeline hydrochloride

SMILES

Cl.CC1=NOC(=N1)[C@]23C[C@H]2CNC3

InChI

InChIKey=LFFMTVIROSODDO-QMGYSKNISA-N
InChI=1S/C8H11N3O.ClH/c1-5-10-7(12-11-5)8-2-6(8)3-9-4-8;/h6,9H,2-4H2,1H3;1H/t6-,8-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C8H11N3O
Molecular Weight 165.1924
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Wed Apr 02 19:27:32 GMT 2025
Edited
by admin
on Wed Apr 02 19:27:32 GMT 2025
Record UNII
TH565G8BVK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Betovumeline hydrochloride
Common Name English
3-Azabicyclo[3.1.0]hexane, 1-(3-methyl-1,2,4-oxadiazol-5-yl)-, hydrochloride (1:1), (1R,5R)-
Preferred Name English
(1R,5R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Systematic Name English
Code System Code Type Description
CAS
1364078-75-0
Created by admin on Wed Apr 02 19:27:32 GMT 2025 , Edited by admin on Wed Apr 02 19:27:32 GMT 2025
PRIMARY
FDA UNII
TH565G8BVK
Created by admin on Wed Apr 02 19:27:32 GMT 2025 , Edited by admin on Wed Apr 02 19:27:32 GMT 2025
PRIMARY
PUBCHEM
165755512
Created by admin on Wed Apr 02 19:27:32 GMT 2025 , Edited by admin on Wed Apr 02 19:27:32 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
The initial study to be conducted under this IND is Study ML-007-014, a hAME/mass balance study, in which ML-007 mixed with a microtracer of [14C]-ML-007 will be coadministered with fesoterodine as individual components in oral solution due to the nature of the clinical study.